Skip to content
lifestyle.mmminimal.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Replimune, Inc.
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
May 30, 2026
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
May 29, 2026
Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2026
Replimune to Present at Two Upcoming Investor Conferences
March 2, 2026
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
February 3, 2026